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Rockville, Maryland, USAIntroduction: Patients with slowly progressive autosomal dominant polycystic kidney disease (ADPKD) are
unlikely to experience outcomes during randomized controlled trials (RCTs). An image classiﬁcation
of ADPKD into typical (diffuse cyst distribution) class 1A to E (by age- and height-adjusted total kidney
volume [TKV]) and atypical (asymmetric cyst distribution) class 2 was proposed for prognostic enrichment
design, recommending inclusion of only classes 1C to 1E in RCTs.
Methods: A post hoc exploratory analysis was conducted of the TEMPO 3:4 Trial, a prospective,
randomized, double-blinded, controlled clinical trial in adult subjects with ADPKD, an estimated creatinine
clearance >60 ml/min and total kidney volume >750 ml.
Results: Due to the entry criteria, the study population of TEMPO 3:4 was enriched for classes 1C-E
(89.5 % of 1436 patients with baseline magnetic resonance images) compared to unselected populations
(e.g., 60.5% of 590 Mayo Clinic patients). The effects of tolvaptan on TKV and eGFR slopes were greater in
classes 1C to E than in 1B. In TEMPO 3:4, tolvaptan reduced TKV and eGFR slopes from 5.51% to 2.80% per
year and from 3.70 to 2.78 ml/min/1.73 m2 per year, and lowered the risk for a composite endpoint of
clinical progression events (hazard ratio ¼ 0.87). Restricting enrollment to classes 1C to E would have
reduced TKV and eGFR slopes from 5.78% to 2.91% per year and from 3.93 to 2.82 ml/min/1.73 m2 per
year, and the risk of the composite endpoint (hazard ratio ¼ 0.84, P ¼ 0.003), with 10.5% fewer patients.
Discussion: Prognostic enrichment strategies such as the entry criteria used for TEMPO3:4 or preferably the
proposed image classiﬁcation should be used in RCTs for ADPKD to increase power and to reduce cost.
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disease and the fourth leading cause of end-stage renal dis-
ease (ESRD) in adults worldwide.1,2 ADPKDpresentswith
large phenotypic variability, resulting in a wide range of
disease severity and progression.3,4 Patients with mild
disease have a good prognosis and may not require
therapy to halt or slow down the progression of ADPKD,
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International Reports (2016) 1, 213–220meaningful beneﬁt. Furthermore, inclusion of patients
with a low risk of progression in clinical trials decreases
the power to detect a treatment effect. Hence, identifying
optimal candidates for enrollment into randomized
controlled trials (RCTs), with progressive disease and
most likely to beneﬁt from an effective therapy is vital.
Studies have shown that total kidney volume (TKV)
predicts renal function decline in patients with
ADPKD, qualifying TKV as a prognostic biomarker.3,5
In fact, kidney volume has been widely used as a
primary or secondary endpoint in multiple clinical
trials.6–15 However, TKV does not always predict
change in renal function, as, for example, in patients
with few large cysts or in patients with renal atrophy213
CLINICAL RESEARCH MV Irazabal et al.: Prognostic Enrichment Design in TEMPO 3:4secondary to ischemia or urinary tract obstruction. We
have recently developed and validated an image clas-
siﬁcation of ADPKD in an attempt to more precisely
deﬁne patients’ risk for disease progression and to
optimize the selection of patients for clinical trials.
According to our classiﬁcation system, class 1
(or typical) patients are those who exhibit classical
bilateral distribution of the disease, whereas class 2
(or atypical) patients may exhibit unilateral, segmental,
asymmetric, or bilateral atypical presentation (class
2A), but also may exhibit bilateral distribution with
acquired unilateral atrophy or bilateral kidney atrophy
(class 2B), based on prespeciﬁed imaging ﬁndings.16 In
class 2 patients, TKV did not predict change in esti-
mated glomerular ﬁltration rate (eGFR) over time.
Patients in class 2A presented with low risk for disease
progression; patients in class 2B without renal
enlargement and with atrophic parenchyma were not
likely to beneﬁt from therapies directed to slowing
kidney growth. In contrast to class 2, TKV and age
predicted change in eGFR over time in class 1 patients.
Moreover, stratiﬁcation of class 1 patients into A, B, C,
D, and E, based on an increasing height-adjusted total
kidney volume (HtTKV) for age, showed that the rate of
eGFR decline and renal survival were signiﬁcantly
different, with patients in class C, D, and E being at
highest risk for eGFR decline. Thus, we recommended
that class 1A, 1B, and 2 patients be excluded for
prognostic enrichment.
The aim of this study was to investigate the effects
that these exclusions would have had on the results of
TEMPO 3:4, a trial already enriched by a maximum age
and minimal TKV, to demonstrate a beneﬁcial effect of
tolvaptan on the progression of ADPKD.
MATERIALS AND METHODS
Study Design
This was a post hoc exploratory analysis of the TEMPO
3:4 clinical trial to investigate the performance of a
previously developed imaging classiﬁcation of ADPKD
for prognostic enrichment design in clinical trials.
TEMPO 3:4 was a prospective, randomized, double-
blinded, controlled clinical trial in adult patients
(1850 years of age) with ADPKD, an estimated
creatinine clearance >60 ml/min, and a total kidney
volume >750 ml. The participants were randomized in
a 2:1 ratio to receive tolvaptan, a V2-receptor antago-
nist, or placebo. The primary outcome was the annual
rate of change in the TKV. Sequential secondary end-
points included a composite of time to clinical pro-
gression (deﬁned as worsening kidney function,
kidney pain, hypertension, and albuminuria) and rate
of kidney function decline. Detailed description of the
TEMPO 3:4 study has been published previously.8,16214All TEMPO 3:4 study participants who met inclu-
sion criteria and underwent randomization (N ¼ 1445)
were considered for this post hoc analysis.8 Nine par-
ticipants were excluded from analysis due to lack of
baseline images (n ¼ 6), patient height (n ¼ 2), or
incorrect ADPKD diagnosis (n ¼ 1). Baseline magnetic
resonance imaging (MRI) studies were used to classify
these patients by means of our classiﬁcation system,
which has been previously published.16 The classiﬁ-
cation into class 1 (typical) and class 2 (atypical) pa-
tients was performed blindly. The kidney volumes
used to stratify the class 1 patients into the 5 subclasses
were the baseline kidney volumes that had been
measured for the parent study. The analysts perform-
ing these measurements were blinded to treatment
allocation.
Classiﬁcation of Study Participants Into Typical
(Class 1) and Atypical (Class 2) Patients
All available baseline magnetic resonance images were
transferred to the Mayo Translational PKD Center and
later retrieved to a work station for further analysis.
Subjects were classiﬁed as class 1 (typical) or class 2
(atypical) cases based on prespeciﬁed imaging ﬁnd-
ings.16 Image classiﬁcations were performed blinded to
clinical data. TKVs were previously measured for the
TEMPO 3:4 study.8 Class 1 ADPKD patients were
further stratiﬁed into 5 subclasses, A to E, based on
HtTKV and age, as previously described.16
Primary and Secondary Endpoints
The primary endpoint was the same as for the TEMPO
3:4 study: the annual rate of percentage change in TKV
over time. TKVs from TEMPO 3:4 were used for this
calculation. The composite secondary endpoint, the
time to investigator-assessed clinical progression as
deﬁned by worsening of kidney function, clinically
signiﬁcant kidney pain, worsening hypertension, and
worsening albuminuria and other secondary endpoints
such as change in the slope of kidney function were
also the same as for TEMPO 3:4 study.8 GFR was esti-
mated using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation. Patients’ character-
istics (i.e., age, sex, race/ethnicity) and laboratory
measurements (i.e., serum creatinine, urine albumin
excretion) were the same as collected for TEMPO 3:4
study.17
Statistical Analysis
TEMPO 3:4 prespeciﬁed primary and secondary end-
points were re-evaluated by image-based classiﬁcation.
Analysis of the primary endpoint compared the
average of individual slopes for TKV between groups
by ﬁtting log10-transformed data on TKV to a linearKidney International Reports (2016) 1, 213–220
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MV Irazabal et al.: Prognostic Enrichment Design in TEMPO 3:4 CLINICAL RESEARCHmixed-effects Laird-Ware model.18 Analysis of slope of
kidney function was similar to slope of TKV. The
analysis of the composite secondary endpoint was
performed with the use of the Andersen-Gill approach
for the extended Cox model, for analysis of time to
multiple events. The P value was provided by the
Wald test.19
RESULTS
Image Classiﬁcation and Baseline Clinical,
Laboratory, and Genetic Characteristics
The baseline magnetic resonance images of 1436
participants in the TEMPO 3:4 clinical trial were
examined. The majority of the patients (96.9%) pre-
sented with typical imaging characteristics of ADPKD
and were classiﬁed as class 1, whereas the remaining
3.1% were classiﬁed as atypical or class 2. The main
baseline clinical, laboratory, and genetic characteristics
are shown in Table 1. Class 1 patients were younger
(39  7 vs. 41  8 years, P < 0.01), were more
frequently hypertensive (83.2% vs. 60.0%, P < 0.001),
and had lower eGFR (81.3  21.6 vs. 90.1  17.6
ml/min/1.73 m2, P < 0.01) at baseline. HtTKV in class 1
and class 2 patients were not signiﬁcantly different
(971  499 vs. 909  483 mL, P ¼ 0.35). The gender
distribution was similar in class 1 patients (47.5%
female), but the proportion of female patients was
higher in class 2 patients (73.3%). Genetic analysis was
available in 53.4% of the patients, of whom 85.4% had
a mutation in the PKD1 gene, 12.1% a mutation in the
PKD2 gene, and 2.5% no mutation detected. The
percentages of cases with a PKD2 mutation and no
mutation detected were higher in class 2 compared to
class 1 patients, whereas that of PKD1 was lower in
class 2 compared to class 1 patients.
Class 1 patients were further stratiﬁed into subclasses
(1AE), as previously described.16 No participants were
classiﬁed as class 1A, thus reﬂecting the inclusion criteria
for enrollment into TEMPO 3:4 (TKV >750 mL, <50
years of age).Most class 1 patients were classiﬁed as 1C¼
38.2% or 1D ¼ 35.4%, followed by 1E ¼ 18.8% and
1B¼ 7.6%. In fact, classes 1C to 1E constituted 89.5% of
the total 1436 patients included in the study. In an un-
selected ADPKD population at the Mayo Clinic (n¼ 590,
age 1680, eGFR 9159 ml/min/1.73 m2), classes 1C to E
accounted for 60.5% of the patients, conﬁrming the
enrichment of TEMPO 3:4 for patients with severe,
rapidly progressing disease. The distribution by class 1B
to 1E was similar between the tolvaptan and placebo
groups (Figure 1). Baseline age decreased from class 1B
through 1E in both treatment groups, whereas TKV
increased. Estimated GFR was similar in all classes and
treatment groups (Table 1). Interestingly, the male/fe-
male ratio increased consistently from 1B to 1E in theKidney International Reports (2016) 1, 213–220 215
Figure 1. Distribution of subjects based on image classiﬁcation in the tolvaptan and placebo treatment arms.
CLINICAL RESEARCH MV Irazabal et al.: Prognostic Enrichment Design in TEMPO 3:4tolvaptan and placebo groups. The percentage of PKD1
cases increased from class 1B to 1E in tolvaptan- and
placebo-treated patients, whereas PKD2 cases decreased
from class 1B to 1E. The rate of NMD decreased in classes
1B to 1D and increased slightly in 1E.
Outcome Measures by Class
Primary Endpoint: TKV Slopes
TEMPO 3:4 had shown a reduction in the rate of TKV
increase from 5.5% to 2.8% per year over the 3-year
duration of the trial. For the current post hoc analysis
of the primary endpoint,8 1270 patients had a baseline
and 1 postrandomization MRI available. The analysis
shows that the TKV slopes increased from class 1B
through class 1E in both treatment arms and conﬁrms
that the rate of total kidney volume growth was lower
in tolvaptan- compared to placebo-treated patients (P¼
0.02 for 1B and P < 0.001 for each of 1C1E) (Table 2).
Treatment effects of tolvaptan in classes 1B through 1E
were not signiﬁcantly different. Tolvaptan did not
reduce the rate of TKV growth in class 2 patients (P ¼
0.88).
Secondary Endpoint: eGFR Slopes
In TEMPO 3:4, tolvaptan slowed the rate of eGFR
decline from 3.70 to 2.72 ml/min/1.73 m2 per year.
For the post hoc analysis of the secondary endpoint, on
treatment slopes were estimated in 1320 patients. The
analysis shows that the rates of eGFR decline increased
from class 1B to 1E in both tolvaptan and placebo-
treated patients. Furthermore, the rates of eGFR
decline were signiﬁcantly lower in the patients ran-
domized to tolvaptan compared to those randomized to
placebo in class 1C, 1D, and 1E patients, but not in class
1B patients (P < 0.001, P ¼ 0.007, P ¼ 0.002, and
P ¼ 0.64, respectively) (Table 3). The treatment effects
216of tolvaptan in classes 1C, 1D, and 1E were not
signiﬁcantly different. Tolvaptan did not decrease the
rate of eGFR decline in class 2 patients (P ¼ 0.75).
Composite Secondary Endpoint: Time to Clinical
Progression
Complications related to ADPKD and associated with
disease progression were grouped into a composite
endpoint deﬁned as time to clinical progression. The
clinical events comprising the composite endpoint were
predetermined and included the following: a 25%
reduction in the inverse of serum creatinine (roughly
equivalent to a 30% decline in eGFR by the CKD-EPI
formula), clinically signiﬁcant kidney pain, worsening
hypertension, and worsening albuminuria. TEMPO 3:4
previously showed fewer ADPKD-related events in
tolvaptan- compared to placebo-treated patients, with a
hazard ratio (HR) of 0.87 (95% conﬁdence interval
[CI] ¼ 0.78, 0.97; P < 0.01). Analysis of the composite
endpoint by class showed a signiﬁcant beneﬁcial effect
in classes 1C (HR ¼ 0.80; 95% CI ¼ 0.67, 0.97; P ¼
0.02) and 1E (HR ¼ 0.77; 95% CI ¼ 0.61, 0.98;
P ¼ 0.03). No signiﬁcant effect was observed in groups
1D (HR ¼ 0.91; 95% CI ¼ 0.76, 1.10; P ¼ 0.33), 1B
(HR ¼ 1.03; 95% CI ¼ 0.67, 1.57; P ¼ 0.91), and 2A
and 2B (HR ¼ 1.71; 95% CI ¼ 0.95, 3.09; P ¼ 0.08)
(Figure 2).
Adverse Events
Frequencies of adverse events, including elevations of
liver enzymes, were not signiﬁcantly different among
the imaging classes.
Outcome Measures by Previous Recommenda-
tion to Exclude/Include From RCTs
To ascertain how implementation of our recommen-
dation to exclude class 1A, 1B, and 2 patients forKidney International Reports (2016) 1, 213–220
Table 2. TKV slopes (percent change per year), by image-based classiﬁcation and treatment group
Class Class 1B Class 1C Class 1D Class 1E Class 2A/2B
Treatment PLC
n ¼ 29
TLV
n ¼ 64
PLC
n ¼ 186
TLV
n ¼ 288
PLC
n ¼ 150
TLV
n ¼ 291
PLC
n ¼ 76
TLV
n ¼ 144
PLC
n ¼ 17
TLV
n ¼ 25
TKV slope (%/yr) 3.25 1.23 5.12 1.79 5.62 3.03 7.75 4.96 2.48 2.27
95% CI 1.50, 5.03 0.30, 2.17 4.35, 5.90 1.26, 2.32 4.58, 6.68 2.47, 3.59 6.16, 9.35 4.03, 5.89 0.34, 5.39 0.11, 4.47
Treatment effect (%/yr) 2.00 3.27 2.52 2.66 0.21
95% CI 3.76, 0.27 4.03, 2.52 3.54, 1.50 4.17, 1.16 3.05, 2.55
P value 0.02 <0.001 <0.001 <0.001 0.88
CI, conﬁdence interval; PLC, placebo treatment group; TKV, total kidney volume.
MV Irazabal et al.: Prognostic Enrichment Design in TEMPO 3:4 CLINICAL RESEARCHprognostic enrichment would have affected the results
of the TEMPO 3:4, we combined classes 1B/2A/2B
(n ¼ 151), which would have been excluded, and
1C/1D/1E (n ¼ 1285), which would have been included
in the trial (n ¼ 1436). We found that tolvaptan had a
beneﬁcial effect in the patients with moderate to severe
disease (1C/1D/1E), reducing the rate of increase in TKV
by 2.79% per year (P < 0.001) and the rate of eGFR
decline by 1.11 ml/min/1.73 m2 per year (P < 0.001).
On the other hand, tolvaptan had only a modest effect
of borderline statistical signiﬁcance on the rate of in-
crease in TKV (1.4% per year, P ¼ 0.052) without a
signiﬁcant effect on the rate of change in eGFR (0.14
ml/min/1.73 m2 per year; P ¼ 0.79) in classes 1B/2A/2B
(Table 4). Moreover, analysis of the secondary com-
posite endpoint showed fewer ADPKD-related events
per 100 person-years of follow-up with tolvaptan than
with placebo only in classes 1C/1D/1E (44 vs. 52; HR ¼
0.84, 95% CI ¼ 0.75, 0.94; P ¼ 0.003) but not in classes
1B/2A/2B (41 vs. 34; HR ¼ 1.20, 95% CI ¼ 0.85, 1.71;
P ¼ 0.30) (Figure 2, Table 5).
DISCUSSION
The progression of ADPKD is characterized by lifetime,
unrelenting development and growth of renal cysts,
renal enlargement, and destruction of renal paren-
chyma, while renal function remains deceptively
normal for decades due to the compensatory capacity of
the surviving nephrons.5 Only at advanced stages
of the disease does the destruction of nephrons exceed
the compensatory capacity of the kidney and an
accelerated decline in kidney function ensues. ThisTable 3. eGFR slopes (ml/min/1.73 m2 per year) by image-based classifica
Class Class 1B Class 1C
Treatment PLC
n ¼ 30
TLV
n ¼ 66
PLC
n ¼ 187
TLV
n ¼ 304 n
eGFR slope
(ml/min/1.73 m2 per yr)
–1.79 –2.10 –3.59 –2.32
95% CI –3.08, –0.51 –2.69, –1.52 –4.18, –3.00 –2.68, –1.95 –4.5
Treatment effect
(ml/min/1.73 m2 per yr)
–0.31 1.27
95% CI –1.60, 0.98 0.68, 1.87
P value 0.64 <0.001
CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; PLC, placebo treatment gro
Kidney International Reports (2016) 1, 213–220pattern of progression constitutes a challenge for the
design of clinical trials because measurements of GFR
are not informative at early stages of the disease, and
interventions at advanced stages, when measurements
of GFR are informative, may be less likely to demon-
strate favorable results.5
A large body of experimental evidence supports the
importance of vasopressin in the pathogenesis of
ADPKD20–27 and provided the rationale for TEMPO
3:4, a phase 3, multicenter, double-blind, placebo-
controlled, 3-year trial to determine whether the
vasopressin V2 receptor antagonist tolvaptan can slow
the growth of the kidneys and the decline of kidney
function and can delay a composite endpoint of events
associated with progression of the disease, including
kidney pain, worsening hypertension, worsening
albuminuria, and 25% reduction in the inverse of
serum creatinine. The design of TEMPO 3:4 relied on
understanding the challenge posed by the typical
course of the disease.17 Inclusion criteria were formu-
lated to enroll patients at a relatively early stage of
disease, deﬁned by an estimated creatinine clearance of
60 ml/min or more and a high likelihood of rapid dis-
ease progression reﬂected by a kidney volume of at
least 750 mL at a relative young age of 50 years or less.
TEMPO 3:4 was the ﬁrst large randomized clinical trial
in ADPKD jointly including age, kidney volume, and
renal function in the inclusion criteria. As a result,
TEMPO 3:4 participants at baseline (39 years, 1690 ml,
and 82 ml/min/1.73 m2)8 were at a later stage of the
disease compared to those in the Suisse trial of siroli-
mus (32 years, 907 mL, and 92 ml/min/1.73 m2)13 or totion and treatment group
Class 1D Class 1E Class 2A/2B
PLC
¼ 152
TLV
n ¼ 299
PLC
n ¼ 78
TLV
n ¼ 161
PLC
n ¼ 17
TLV
n ¼ 26
–3.89 –2.99 –4.93 –3.46 –1.66 –1.34
4, –3.24 –3.34, –2.64 –5.87, –3.99 –4.00, –2.92 –3.63, 0.32 –2.63, –0.04
0.89 1.47 0.32
0.25, 1.54 0.53, 2.41 –1.65, 2.30
0.007 0.002 0.75
up; TKV, total kidney volume.
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Figure 2. Time to multiple composite autosomal dominant polycystic kidney disease (ADPKD) events by image classiﬁcation: hazard ratios (95%
conﬁdence intervals) for the secondary endpoint of ADPKD-related events by image classiﬁcation and exclusion/inclusion recommended
groups.
CLINICAL RESEARCH MV Irazabal et al.: Prognostic Enrichment Design in TEMPO 3:4the Polycystic Kidney Disease Treatment Network
(HALT PKD) Study A blood pressure trial (37 years,
1210 ml, and 92 ml/min/1.73 m2),28 but at an earlier
stage of the disease compared to the everolimus trial (45
years, 1970 mL, 55 ml/min/1.73 m2)14 or to the Poly-
cystic Kidney Disease Treatment Network (HALT
PKD) Study B blood pressure trial (49 years, 48 ml/min/
1.73 m2).29Table 4. TKV and eGFR slopes by recommendation in Irazabal
et al.,17and treatment group
Recommendation to
exclude/include
Patients to exclude
1Aa/1B/2A/2Bb
Patients to include
1C/1D/1E
Treatment PLC
n ¼ 46
TLV
n ¼ 89
PLC
n ¼ 412
TLV
n ¼ 723
TKV slope (%/yr) 2.99 1.53 5.78 2.91
95% CI 1.51, 4.48 0.63, 2.43 5.18, 6.39 2.55, 3.28
Treatment effect (%/yr) –1.44 –2.79
95% CI –2.91, 0.01 –3.38, –2.20
P value 0.052 <0.001
Treatment PLC
n ¼ 47
TLV
n ¼ 92
PLC
n ¼ 417
TLV
n ¼ 764
eGFR slope
(ml/min/1.73 m2 per yr)
–1.74 –1.88 –3.93 –2.82
95% CI –2.81, –0.67 –2.44, –1.33 –4.33, –3.53 –3.05, –2.59
Treatment effect
(ml/min/1.73 m2 per yr)
–0.14 1.11
95% CI –1.21, 0.93 0.71, 1.51
P value 0.79 <0.001
CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate (estimated by CKD-EPI
equation); PLC, placebo treatment group; TKV, total kidney volume.
aBecause of the entry criteria, none of the patients enrolled into TEMPO 3:4 were class
1A.
bOnly 1 patient classified as 2B in this study.
218Although the entry criteria for TEMPO 3:4 jointly
considered age, TKV, and eGFR to enroll patients likely
to be informative and to increase the power to detect a
treatment effect, a more precise classiﬁcation of disease
severity has been recently proposed with the same
goal.16 The purpose of the post hoc analysis presented
in this manuscript was to determine how the use of this
classiﬁcation in TEMPO 3:4 would have affected the
results of the trial. The analysis conﬁrmed that the
entry criteria used in TEMPO 3:4 were successful in
selecting a population enriched for patients with se-
vere, rapidly progressing disease as evidenced by the
low number of class 1A (0%), class 1B (106 or 7.4%),
and class 2 (45 or 3.1%) patients, possibly contributing
to the positive results of the trial. The analysis also
showed that exclusion of these 151 patients (10.5%
overall) would have resulted in numerically although
not signiﬁcantly higher treatment effects on TKV
slopes (2.79% per year, P < 0.001, compared to 2.71%
per year, P < 0.001) and on treatment eGFR slopes (1.11
ml/min/1.73 m2 per year, P < 0.001, compared to 0.98
ml/min/1.73 m2 per year, P < 0.001).
At the request of the Food and Drug Administration,
the power calculation for the TEMPO 3:4 trial was
based on the key secondary endpoint, using an a level
of 0.01. The trial was thus powered to around 80%,
with an assumption of a hazard ratio of 0.8 favorable to
tolvaptan in the key secondary endpoint. When the
trial was unblinded, the observed hazard ratio wasKidney International Reports (2016) 1, 213–220
Table 5. Composite secondary endpoint: time to clinical progression
by recommendation in Irazabal et al.,16 and treatment group
Recommendation to
exclude/include
Patients to exclude
1Aa/1B/2A/2Bb
Patients to include
1C/1D/1E
Treatment
(no. of subjects)
PLC
48
TLV
103
PLC
433
TLV
851
ADPKD-related composite
(no. of total events)
45 106 620 936
Events/100 person-yr 33.52 40.93 51.93 44.36
HR (95% CI) 1.20 (0.85, 1.71) 0.84 (0.75, 0.94)
P value 0.3028 0.0032
Treatment
(no. of subjects)
PLC
47
TLV
97
PLC
427
TLV
813
Worsening kidney function
(no. of total events)
1 2 63 41
Events/100 person-yr 0.75 0.77 5.3 1.95
HR (95% CI) 1.06 (0.10, 11.27) 0.37 (0.25, 0.55)
P value 0.9623 <0.0001
Treatment
(no. of subjects)
PLC
48
TLV
103
PLC
433
TLV
851
Clinically signiﬁcant kidney pain
(no. of total events)
8 11 89 102
Events/100 person-yr 5.96 4.25 7.46 4.83
HR (95% CI) 0.71 (0.27, 1.83) 0.64 (0.46, 0.90)
P value 0.4745 0.0109
Treatment
(no. of subjects)
PLC
48
TLV
103
PLC
433
TLV
851
Worsening hypertension
(no. of total events)
30 72 396 658
Events/100 person-yr 22.35 27.80 33.17 31.19
HR (95% CI) 1.22 (0.78, 1.93) 0.92 (0.79, 1.08)
P value 0.3899 0.3077
Treatment
(no. of subjects)
PLC
48
TLV
103
PLC
433
TLV
851
Worsening albuminuria
(no. of total events)
7 23 96 170
Events/100 person-yr 5.21 8.88 8.04 8.06
HR (95% CI) 1.69 (0.79, 3.61) 0.99 (0.79, 1.23)
P value 0.1793 0.8965
ADPKD, autosomal dominant polycystic kidney disease; CI, conﬁdence interval;
HR, hazard ratio; PLC, placebo treatment group; TLV, tolvaptan treatment group.
Signiﬁcant results are highlighted in bold.
aBecause of the entry criteria, none of the patients enrolled into TEMPO 3:4 were
class 1A.
bOnly 1 patient classified as 2B in this study.
MV Irazabal et al.: Prognostic Enrichment Design in TEMPO 3:4 CLINICAL RESEARCH0.865, with a P value of 0.0095. Thus the post hoc po-
wer of the TEMPO 3:4 trial was 51% for an a level of
0.01. Had the trial been designed with a patient pop-
ulation based on Irazabal classes 1C/1D/1E, the post hoc
power would have been 70% for an a level of 0.01,
assuming a hazard ratio of 0.84 as observed in the
analysis presented herein, and everything else
remaining unchanged. For a more commonly used a
value of 0.05, the post hoc power of TEMPO 3:4 would
be 72%, and the post hoc power of the presumed
TEMPO 3:4 trial with Irazabal classes 1C/1D/1E would
have been 88%.
It is important to point out that the Irazabal classi-
ﬁcation for prognostic enrichment requires only the
application of an algorithm available online, which
is based on TKV, age, and height of the patient, data
which were already available at the time of screening inKidney International Reports (2016) 1, 213–220TEMPO 3:4. It does not require additional images or
expense. Therefore, it is reasonable to conclude that it
would have enhanced the efﬁciency of the trial by
providing numerically higher treatment effects on the
rates of kidney growth and eGFR decline and greater
power to detect a signiﬁcant effect on the key sec-
ondary endpoint, with a lower number of patients and
consequently lower cost. Because only patients with
rapidly progressive ADPKD are likely to beneﬁt from
and be treated with novel therapies as these become
available, the generalizability of the results does not
become a problem when entry into clinical trials is
restricted to classes 1C/1D/1E.
This study has limitations inherent to a post hoc
analysis and was not powered to analyze the endpoints
by class of disease severity. Furthermore, the entry
criteria for TEMPO 3:4 had already been selected to
enroll a cohort of patients with ADPKD and rapidly
progressive disease. Nevertheless, the analysis suggests
that had enrollment been restricted to class 1C, 1D, and
1E patients, similar or slightly stronger treatment ef-
fects would have been obtained with 10.5% fewer
patients, and further supports the use of prognostic
enrichment strategies such as the image classiﬁcation in
the design of RCTs for ADPKD to increase power and
potentially decrease costs.
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